

## ABSTRACT

The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H<sub>3</sub> Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Na<sub>i</sub>) by inhibiting the Na<sup>+</sup>/H<sup>+</sup> exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca<sup>2+</sup> channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H<sub>3</sub> Receptor agonist with a pharmaceutical carrier.